Archive | Biopharmaceuticals

Market Grinds Up- With Profit Taking In Some Biotech MO Stocks

see Sell-Off Evident In Big Winners-Technicals Are Very Important In Here The 2013 rally trickled up today with the DOW and S&P up, but off its highs. NASDAQ is flat. The media trash talk has stoked up with many well known pundits and strategists urging caution but others repeating the worn mantra “don’t fight the tape, […]

Continue Reading 0

Bull Run Gets A Second Wind on A Frantic Friday: Many Life Science Stocks Are At All Time Highs

http://crochetedbuddies.com/category/paid-crochet-patterns/beach-sealife/ Dow 14,000 and General Market Euphoria Lifts All Stocks: Has the Bond Bubble Burst? Life Science stocks ran with the general market today and with all the green screens you’d think it was St. Paddy’s Day. The concern now is that everybody is bullish and think equities is the place to be invested. European crises […]

Continue Reading 0

Genomics Heats Up With LIFE Technologies Play

isotretinoin buy online Future Clinical Potential of Genomics Attracts Financing and Deals Life Technologies (LIFE $65) was up 3.6% again today on news that ThermoFisher (TMO $71.51) is studying a takeover. The market cap of LIFE is $10.7B while that of ThermoFisher is $25B. Private equity firms are also looking at LIFE which is up 34% YTD. ThermoFisher […]

Continue Reading 0

Biotech Bull Market Rolls Merrily Along- Funds Are the Engine

Bullish Mentality Drives Usual MO-vers: PCYC, MDVN, REGN, SGEN  It is hard to add biotech stocks to your portfolio at these elevated levels but big players like Fidelity, Cap World, JPMorgan, T.Rowe Price and selected hedge funds- Orbimed, Baker Bros, etc can drive their holdings up more on any good news. Case in point is […]

Continue Reading 0

A Bit of A Sell-Off in High Flyers: ALXN, REGN

A double top in the biotechnology sector could be developing although many mid and small cap stocks are in the green. We are still at or near the October highs in the sector but the seasonality effect is waning (strong November -January performance). Moreover many of the top performers in 2012 are owned by all […]

Continue Reading 0

Global “Risk-On” Rally Across Most Sectors Especially Biotechnology

The Bi-Partisan Cliff Deal Nobody Likes (Except the Market) Investors like the tax deal as it is favorable to investors despite the tax increases. Stocks are holding their gains after a “mini-fiscal” cliff deal that drove the Dow and S&P up 1.7% and NASDAQ up 2.4%. Life science stocks soared as they usually trade with the […]

Continue Reading 0

Rayno Biopharmaceutical Focus Stocks YTD: Top Performers include AMRI,GILD, REGN

Outstanding Year for Biotechnology -Average Performance is up 35% YTD Many Rayno Life Science Stocks have outperformed the sector and the ETFs: Albany Molecular Inc. (AMRI), a contract research organization with long term experience in drug discovery, development and manufacturing soared 82% YTD on improved financial results.The stock is a turnaround story and is still […]

Continue Reading 0

Another Stealth Rally In Biopharmaceuticals: AMGN IBB REGN VPHM

Rayno Life Science Stocks Move Higher Biotech stocks are ignoring the volatility from the political fray today with big moves in many Rayno Life Science stocks and a 1.5% move in the bellwether ETF (IBB).The tech heavy QQQ lagged up only 0.7%. Overall, despite the negative comments on the fiscal cliff negotiations the market believes […]

Continue Reading 0

Rayno Life Science Mid-day Movers: AMRI, ASTX, CPHD, ILMN, REGN

Markets Are Back To Fretting About Fiscal Cliff Bernanke scolded Congress on the fiscal cliff and markets turned down. Despite a lackluster market down about 0.3% there is a lot of green in biotech. Among the winners in the Rayno Life Science universe are: Albany Molecular (AMRI $4.21) broke through to new highs up 43% YTD. […]

Continue Reading 0

Raygent Biopharmaceutical Portfolio: Celgene (CELG) and Gilead (GILD) Ignite Rally

A languishing biotech sector rallied today with clinical news with Hepatitis C (HCV) drugs. The Rayno Biopharma Portfolio was up 2.4% led by Gilead Sciences (GILD) up 11.5%, Regeneron (REGN) up 3.3% and ViroPharma (VPHM) up 3.2%. Gilead shares were up $7.50 on favorable Phase 2 results with their antiviral drug GS-5885 in combination with ribavirin. […]

Continue Reading 0